Total Payments
$4,446
2024 Payments
$736.75
Companies
34
Transactions
245
Medicare Patients
6,207
Medicare Billing
$623,535
Payment Breakdown by Category
Food & Beverage$4,446 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,446 | 245 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,195 | 85 | $0 (2024) |
| Inspire Medical Systems, Inc. | $388.64 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $365.63 | 25 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $328.91 | 12 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $323.08 | 17 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $307.83 | 29 | $0 (2019) |
| GENZYME CORPORATION | $172.21 | 8 | $0 (2024) |
| Vapotherm Inc | $148.89 | 3 | $0 (2022) |
| Mallinckrodt Hospital Products Inc. | $141.96 | 7 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $123.06 | 8 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $736.75 | 29 | GlaxoSmithKline, LLC. ($133.33) |
| 2023 | $935.59 | 46 | GlaxoSmithKline, LLC. ($349.59) |
| 2022 | $803.88 | 49 | GlaxoSmithKline, LLC. ($291.42) |
| 2021 | $601.38 | 36 | AstraZeneca Pharmaceuticals LP ($128.45) |
| 2020 | $286.88 | 18 | GlaxoSmithKline, LLC. ($129.98) |
| 2019 | $438.69 | 22 | Inspire Medical Systems, Inc. ($131.26) |
| 2018 | $275.96 | 11 | Inspire Medical Systems, Inc. ($136.48) |
| 2017 | $367.22 | 34 | Sunovion Pharmaceuticals Inc. ($220.99) |
All Payment Transactions
245 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $119.60 | General |
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: Respiratory | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Respiratory | ||||||
| 09/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: RESPIRATORY | ||||||
| 08/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Immunology | ||||||
| 07/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $33.20 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $5.44 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $30.72 | General |
| Category: RESPIRATORY | ||||||
| 07/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: Immunology | ||||||
| 07/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $3.47 | General |
| Category: RESPIRATORY | ||||||
| 06/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $30.82 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $25.85 | General |
| Category: RESPIRATORY | ||||||
| 05/08/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: RESPIRATORY | ||||||
| 05/08/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: RESPIRATORY | ||||||
| 04/01/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $92.13 | General |
| Category: NEUROLOGY | ||||||
| 03/29/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: RESPIRATORY | ||||||
| 03/27/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $37.58 | General |
| Category: HFCWO | ||||||
| 03/20/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: Respiratory | ||||||
| 03/14/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: RESPIRATORY | ||||||
| 03/06/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: RESPIRATORY | ||||||
| 02/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: RESPIRATORY | ||||||
| 02/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: RESPIRATORY | ||||||
| 02/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $30.22 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,440 | 1,966 | $266,775 | $121,495 |
| 2022 | 17 | 1,473 | 2,155 | $321,554 | $150,139 |
| 2021 | 19 | 1,736 | 2,646 | $391,778 | $197,299 |
| 2020 | 20 | 1,558 | 2,200 | $314,830 | $154,601 |
Total Patients
6,207
Total Services
8,967
Medicare Billing
$623,535
Procedure Codes
90
All Medicare Procedures & Services
90 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 189 | 336 | $58,800 | $29,583 | 50.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 146 | 294 | $36,750 | $17,374 | 47.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 81 | 179 | $26,850 | $16,270 | 60.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 34 | 56 | $18,200 | $9,193 | 50.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 61 | 65 | $17,875 | $8,521 | 47.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 73 | 76 | $13,300 | $7,464 | 56.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 69 | 79 | $9,875 | $4,885 | 49.5% |
| G0398 | Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation | Office | 2023 | 21 | 21 | $10,500 | $4,283 | 40.8% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 124 | 179 | $13,425 | $3,361 | 25.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $7,750 | $3,293 | 42.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 70 | 79 | $5,925 | $3,101 | 52.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 71 | 76 | $4,560 | $2,894 | 63.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 19 | $4,180 | $2,600 | 62.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 47 | 61 | $7,015 | $2,308 | 32.9% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 56 | 57 | $4,275 | $1,725 | 40.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 55 | 57 | $7,125 | $1,526 | 21.4% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 49 | 53 | $14,575 | $1,204 | 8.3% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 72 | 72 | $1,800 | $653.17 | 36.3% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 71 | 71 | $1,420 | $478.33 | 33.7% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 61 | 63 | $1,315 | $390.96 | 29.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 26 | 26 | $780.00 | $201.11 | 25.8% |
| 94664 | Evaluation of use of breathing device | Office | 2023 | 15 | 16 | $480.00 | $187.20 | 39.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 184 | 324 | $56,629 | $28,807 | 50.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 135 | 308 | $46,200 | $24,147 | 52.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 172 | 369 | $46,125 | $20,112 | 43.6% |
About Dr. Gary Kaplan, MD
Dr. Gary Kaplan, MD is a Pulmonary Disease healthcare provider based in Willoughby Hills, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023102324.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Kaplan, MD has received a total of $4,446 in payments from pharmaceutical and medical device companies, with $736.75 received in 2024. These payments were reported across 245 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($4,446).
As a Medicare-enrolled provider, Kaplan has provided services to 6,207 Medicare beneficiaries, totaling 8,967 services with total Medicare billing of $623,535. Data is available for 4 years (2020–2023), covering 90 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Willoughby Hills, OH
- Active Since 10/03/2006
- Last Updated 02/08/2024
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023102324
Products in Payments
- TRELEGY ELLIPTA (Drug) $559.67
- DUPIXENT (Biological) $501.12
- NUCALA (Biological) $375.34
- Inspire Upper Airway Stimulation System (Device) $267.74
- UTIBRON (Drug) $182.30
- BREZTRI (Drug) $172.47
- ANORO (Drug) $136.67
- STIOLTO RESPIMAT (Drug) $135.76
- TEZSPIRE (Biological) $131.74
- ACTHAR (Biological) $125.20
- INSPIRE (Device) $120.90
- OFEV (Drug) $104.87
- XOLAIR (Biological) $104.62
- AREXVY (Drug) $83.58
- SPIRIVA RESPIMAT (Drug) $82.45
- VAPOTHERM (Device) $78.56
- FASENRA (Biological) $76.72
- LONHALA MAGNAIR (Drug) $73.21
- Xolair (Biological) $72.77
- YUPELRI (Drug) $69.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.